Logo

Sanofi Presents Results of Amlitelimab (KY1005) in P-IIa Study for the Treatment of Moderate-To-Severe Atopic Dermatitis at EADV 2021

Share this

Sanofi Presents Results of Amlitelimab (KY1005) in P-IIa Study for the Treatment of Moderate-To-Severe Atopic Dermatitis at EADV 2021

Shots:

  • The P-IIa study evaluates amlitelimab (IV- low/high dose- q4w over 12wks.) vs PBO in 88 patients with mod. to sev. AD inadequately controlled with topical therapies
  • The co-primary EPs include @16wks.- improvement in avg. EASI from baseline (80%/70% vs 49%) in LD/HD- no difference in responses was observed in both doses & the overall rate of TEAEs (35%/17% vs 31%) respectively
  • The 2EPs includes @16wks.- (44%/ 37% vs 8%) patients with LD/HD achieved a score of 0 or 1 on vIGA scale & maintained response. In both doses- (59%/52% vs 25%) & (33%/30% vs 13%) patients achieved ≥75% & 90% skin improvement (EASI-75) & (EASI-790)- improvement in mean percent CFB in SCORAD (60%/59% vs 37%) respectively

  | Ref: Sanofi | Image: Campaign India

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions